CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

Discover why CLLS is a top speculative Buy, with promising CAR-T therapies, strong big pharma partnerships, and attractive ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

India's GenAI infrastructure is being built, but can a public-private partnership outpace the trillion-dollar budgets of US ...

Exagamglogene autotemcel helped children with beta thalassemia achieve transfusion independence and prevented vaso-occlusive crises among those with sickle cell disease in a pair of phase 3 ...

The Shareholders Foundation, Inc. announces that a deadline is coming up in the lawsuit for certain investors in shares of Skye Bioscience, Inc.

Jesse Tettero presented data supporting the use of a measurable residual disease (MRD) surrogate endpoint in acute myeloid leukemia (AML) research. Through the Harmony Alliance study of 1,858 pooled ...